Ute Hegenbart
- Hematology top 0.1%
- Multiple Myeloma Research and Treatments 56
- Hematopoietic Stem Cell Transplantation 56
- Chronic Myeloid Leukemia Treatments 25
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 30
- Nephrology top 0.5%
- Parathyroid Disorders and Treatments 26
- Transplantation top 1%
- Molecular Biology top 1%
- Amyloidosis: Diagnosis, Treatment, Outcomes 160
- Protein Kinase Regulation and GTPase Signaling 20
-
- Neuroendocrine Tumor Research Advances 23
- Co-authors
- Stefan SchönlandAnthony D. HoHartmut GoldschmidtGiovanni PalladiniGiampaolo MerliniArnt V. KristenChristoph KimmichChristoph Röcken
- Cited by
- HematologyGeneticsNephrology
- Partner nations
- GermanyUnited StatesItaly
In The Last Decade
Ute Hegenbart
262 papers receiving 9.4k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Hematology 4.1k
- Genetics 2.0k
- Nephrology 1.3k
- Transplantation 246
- Molecular Biology 5.8k
Countries citing papers authored by Ute Hegenbart
This map shows the geographic impact of Ute Hegenbart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Hegenbart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Hegenbart more than expected).
Fields of papers citing papers by Ute Hegenbart
This network shows the impact of papers produced by Ute Hegenbart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Hegenbart. The network helps show where Ute Hegenbart may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ute Hegenbart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 9 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 8 | |
| 6 | 2023 | 2 | |
| 7 | 2022 | 13 | |
| 8 | 2022 | 27 | |
| 9 | 2021 | 83 | |
| 10 | 2021 | 56 | |
| 11 | 2021 | 9 | |
| 12 | 2020 | 61 | |
| 13 | 2020 | 12 | |
| 14 | HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS | 2017 | 1 |
| 15 | 2012 | 42 | |
| 16 | 2011 | 118 | |
| 17 | 2007 | 79 | |
| 18 | 2007 | 99 | |
| 19 | 2005 | 181 | |
| 20 | 2003 | 21 |
About Ute Hegenbart
Ute Hegenbart is a scholar working on Hematology, Genetics and Nephrology, having authored 281 papers that have together received 9.5k indexed citations. Recurring topics across this work include Amyloidosis: Diagnosis, Treatment, Outcomes (160 papers), Multiple Myeloma Research and Treatments (56 papers), Hematopoietic Stem Cell Transplantation (56 papers), Chronic Lymphocytic Leukemia Research (30 papers), Parathyroid Disorders and Treatments (26 papers), Chronic Myeloid Leukemia Treatments (25 papers), Neuroendocrine Tumor Research Advances (23 papers) and Protein Kinase Regulation and GTPase Signaling (20 papers). The work is most often cited by research in Hematology (4.1k citations), Genetics (2.0k citations) and Nephrology (1.3k citations). Ute Hegenbart has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Stefan Schönland, Anthony D. Ho, Hartmut Goldschmidt, Giovanni Palladini, Giampaolo Merlini, Arnt V. Kristen, Christoph Kimmich, Christoph Röcken, Hugo A. Katus and Axel Benner. Their work appears in journals such as Blood, Amyloid, Bone Marrow Transplantation, Journal of Clinical Oncology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.